期刊文献+

Helicobacter pylori neutrophil-activating protein:From molecular pathogenesis to clinical applications 被引量:10

Helicobacter pylori neutrophil-activating protein:From molecular pathogenesis to clinical applications
下载PDF
导出
摘要 Helicobacter pylori (H. pylori) neutrophil-activating protein (HP-NAP) was originally identified as a virulence factor of H. pylori for its ability to activate neutrophils to generate respiratory burst by releasing reactive oxygen species. Later on, HP-NAP was also found to be involved in the protection of H. pylori from DNA damage, supporting the survival of H. pylori under oxidative stress. This protein is highly conserved and expressed by virtually all clinical isolates of H. pylori. The majority of patients infected with H. pylori produced antibodies specific for HP-NAP, suggesting its important role in immunity. In addition to acting as a pathogenic factor by activating the innate immunity through a wide range of human leukocytes, including neutrophils, monocytes, and mast cells, HP-NAP also mediates adaptive immunity through the induction of T helper cell type I responses. The pro-inflammatory and immunomodulatory properties of HP-NAP not only make it play an important role in disease pathogenesis but also make it a potential candidate for clinical use. Even though there is no convincing evidence to link HP-NAP to a disease outcome, recent findings supporting the pathogenic role of HP-NAP will be reviewed. In addition, the potential clinical applications of HP-NAP in vaccine development, clinical diagnosis, and drug development will be discussed. Helicobacter pylori(H.pylori)neutrophil-activating protein(HP-NAP)was originally identified as a virulence factor of H.pylori for its ability to activate neutrophils to generate respiratory burst by releasing reactive oxygen species.Later on,HP-NAP was also found to be involved in the protection of H.pylori from DNA damage,supporting the survival of H.pylori under oxidative stress.This protein is highly conserved and expressed by virtually all clinical isolates of H.pylori.The majority of patients infected with H.pylori produced antibodies specific for HP-NAP,suggesting its important role in immunity.In addition to acting as a pathogenic factor by activating the innate immunity through a wide range of human leukocytes,including neutrophils,monocytes,and mast cells,HP-NAP also mediates adaptive immunity through the induction of T helper cell typeⅠresponses.The pro-inflammatory and immunomodulatory properties of HP-NAP not only make it play an important role in disease pathogenesis but also make it a potential candidate for clinical use.Even though there is no convincing evidence to link HP-NAP to a disease outcome,recent findings supporting the pathogenic role of HP-NAP will be reviewed.In addition,the potential clinical applications of HP-NAP in vaccine development,clinical diagnosis,and drug development will be discussed.
作者 Hua-Wen Fu
出处 《World Journal of Gastroenterology》 SCIE CAS 2014年第18期5294-5301,共8页 世界胃肠病学杂志(英文版)
基金 Supported by National Science Council of Taiwan,No.NSC101-2311-B-007-007
  • 相关文献

参考文献14

  • 1Theodora Choli-Papadopoulou,Filippos Kottakis,Georgios Papadopoulos,Stefanos Pendas.Helicobacter pylori neutrophil activating protein as target for new drugs against H.pylori inflammation[J].World Journal of Gastroenterology,2011,17(21):2585-2591. 被引量:5
  • 2李建芳,彭正华,肖红剑,罗娜,杨增福,李健峰,徐维明.幽门螺杆菌napA基因在乳酸菌中的表达及免疫原性分析[J].中国生物工程杂志,2008,28(5):104-110. 被引量:10
  • 3Sufi HZ Rahman,M Golam Azam,M Anisur Rahman,MS Arfin,M Mahbub Alam,Tareq M Bhuiyan,Nasim Ahmed,Motiur Rahman,Shamsun Nahar,MS Hassan.Non-invasive diagnosis of H pylori infection: Evaluation of serological tests with and without current infection marker CIM[J].World Journal of Gastroenterology,2008,14(8):1231-1236. 被引量:4
  • 4Bo Sun Zhao-Shen Li Zhen-Xing Tu Guo-Ming Xu Yi-Qi Du.Construction of an oral recombinant DNA vaccine from H pylori neutrophil activating protein and its immunogenicity[J].World Journal of Gastroenterology,2006,12(43):7042-7046. 被引量:4
  • 5Gaia Codolo,Fleur Bossi,Paolo Durigutto,Chiara Della Bella,Fabio Fischetti,Amedeo Amedei,Francesco Tedesco,Sofia D’Elios,Marco Cimmino,Alessandra Micheletti,Marco A. Cassatella,Mario M. D’Elios,Marina de Bernard.Orchestration of Inflammation and Adaptive Immunity in Borrelia burgdorferi –Induced Arthritis by Neutrophil‐Activating Protein A[J].Arthritis & Rheumatism.2013(5)
  • 6Shin‐ichi Yokota,Nariaki Toita,Soh Yamamoto,Nobuhiro Fujii,Mutsuko Konno.Positive Relationship Between a Polymorphism in H elicobacter pylori Neutrophil‐Activating Protein A Gene and Iron‐Deficiency Anemia[J].Helicobacter.2012(2)
  • 7Ianko D. Iankov,Alan R. Penheiter,Stephanie K. Carlson,Evanthia Galanis.Development of monoclonal antibody-based immunoassays for detection of Helicobacter pylori neutrophil-activating protein[J].Journal of Immunological Methods (-).2012(1-2)
  • 8Gaia Codolo,Matteo Fassan,Fabio Munari,Andrea Volpe,Piefrancesco Bassi,Massimo Rugge,Francesco Pagano,Mario Milco D’Elios,Marina Bernard.HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response[J].Cancer Immunology Immunotherapy.2012(1)
  • 9Peter Malfertheiner,Michael Selgrad.Helicobacter pylori infection and current clinical areas of contention[J].Current Opinion in Gastroenterology.2010(6)
  • 10ToniAebischer,Thomas F.Meyer,Leif P.Andersen.Inflammation, Immunity, and Vaccines for Helicobacter[J].Helicobacter.2010

二级参考文献63

  • 1焦志勇,陈旻湖,朱森林,陈洁,李国庆,陈为,胡品津.表达幽门螺杆菌NAP蛋白的减毒沙门疫苗菌株预防幽门螺杆菌感染[J].中国人兽共患病学报,2006,22(7):629-632. 被引量:5
  • 2姚晓英,李大金,袁敏敏.表达hCGβ的重组乳酸杆菌经阴道免疫小鼠后的体液免疫应答[J].中华微生物学和免疫学杂志,2006,26(7):659-664. 被引量:8
  • 3[25]Casswall TH,Nilsson HO,Bergstrom M,Aleljung P,Wadstrom T,Dahlstrom AK,Albert MJ,Sarker SA.Evaluation of serology,13C-urea breath test,and polymerase chain reaction of stool samples to detect Helicobacter pylori in Bangladeshi children.J Pediatr Gastroenterol Nutr 1999; 28:31-36
  • 4[26]Sarker SA,Nahar S,Rahman M,Bardhan PK,Nair GB,Beglinger C,Gyr N.High prevalence of cagA and vacA seropositivity in asymptomatic Bangladeshi children with Helicobacter pylori infection.Acta Paediatr 2004; 93:1432-1436
  • 5[27]Rahman M,Mukhopadhyay AK,Nahar S,Datta S,Ahmad MM,Sarker S,Masud IM,Engstrand L,Albert MJ,Nair GB,Berg DE.DNA-level characterization of Helicobacter pylori strains from patients with overt disease and with benign infections in Bangladesh.J Clin Microbiol 2003; 41:2008-2014
  • 6[28]Laheij RJ,Straatman H,Jansen JB,Verbeek AL.Evaluation of commercially available Helicobacter pylori serology kits:a review.J Clin Microbiol 1998; 36:2803-2809
  • 7[29]Meijer BC,Thijs JC,Kleibeuker JH,van Zwet AA,Berrelkamp RJ.Evaluation of eight enzyme immunoassays for detection of immunoglobulin G against Helicobacter pylori.J Clin Microbiol 1997; 35:292-294
  • 8[30]Leung WK,Chan FK,Falk MS,Suen R,Sung JJ.Comparison of two rapid whole-blood tests for Helicobacter pylori infection in Chinese patients.J Clin Microbiol 1998; 36:3441-3442
  • 9[31]Graham DY,Evans DJ Jr,Peacock J,Baker JT,Schrier WH.Comparison of rapid serological tests (FlexSure HP and QuickVue) with conventional ELISA for detection of Helicobacter pylori infection.Am J Gastroenterol 1996; 91:942-948
  • 10[32]Lepper PM,Moricke A,Vogt K,Bode G,Trautmann M.Comparison of different criteria for interpretation of immunoglobulin G immunoblotting results for diagnosis of Helicobacter pylori infection.Clin Diagn Lab Immunol 2004; 11:569-576

共引文献21

同被引文献50

引证文献10

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部